The reiteration of a Buy rating and maintenance of a $51 price target by HC Wainwright & Co. analyst Raghuram Selvaraju indicates a positive outlook for Genmab's stock in the short term. This news is important for investors as it provides an expert opinion on the stock's potential performance.